ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2016/026352, filed Apr 7, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,787,515 | ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy In force · High confidence | Takeda Pharmaceutical Company Limited | In force | High confidence | ||
| US 12,435,146 | ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy In force · High confidence | Shire Human Genetic Therapies, Inc. | In force | High confidence | ||
| Application 16/991,762 | ANTI-FLT-1 Antibodies for Treating Duchenne Muscular Dystrophy Abandoned Abandoned Apr 26, 2023 | Takeda Pharmaceutical Company Limited | Abandoned | Abandoned Apr 26, 2023 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Shire LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.